Absorption

T _max is 2 to 5 h. Oral bioavailability is approximately 52%.

Distribution

Protein binding is 96.3%.

Metabolism

Extensively metabolized in liver by CYP3A to sulphone metabolite and CYP2C19 to desmethyl rabeprazole. Thioether and sulphone metabolites are formed by reduction of rabeprazole. These metabolites do not have significant antisecretory activity. CYP2C19 exhibits genetic polymorphism caused by deficiency in some subpopulations (white patients, 3% to 5%; Asian patients, 17% to 20%).

Elimination

Plasma half-life is 1 to 2 h. Eliminated in urine (90% as thioether carboxylic acid, glucuronide, and mercapturic acid); remainder recovered in feces. No unchanged drug recovered.

INDICATION  : The  management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.

DOSAGE:  As directed by the physician.

SIDE EFFECTS:  Irritability, Dry mouth, Headache, Loss of interest in sex, Breast pain or tenderness, Abnormal heart rhythm, Drowsiness, Abnormal milk discharge from breast, Diarrhoea.